New drug targets troubled immune cells in autoimmune diseases
NCT ID NCT06977724
Summary
This early-stage study is testing an experimental drug called ABBV-319 in adults with lupus or Sjogren's disease, which are autoimmune conditions where the body's immune system attacks its own tissues. The main goals are to find a safe dose, see how the body processes the drug, and check if it reduces certain overactive immune cells. About 36 participants will receive two doses of the drug three weeks apart and be monitored for nearly a year.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Amsterdam UMC, locatie AMC /ID# 274286
RECRUITINGAmsterdam, North Holland, 1105 AZ, Netherlands
-
Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 275836
RECRUITINGTampa, Florida, 33606, United States
-
Life Clinical Trials /ID# 276050
RECRUITINGMargate, Florida, 33063, United States
-
Private Practice - Dr. Ramesh C. Gupta I /ID# 275826
RECRUITINGMemphis, Tennessee, 38119, United States
Contact Phone: •••-•••-••••
-
Universitair Medisch Centrum Utrecht /ID# 273398
RECRUITINGUtrecht, 3584 CX, Netherlands
Conditions
Explore the condition pages connected to this study.